{
    "data": [
        {
            "id": "4402612",
            "title": "Pfizer's 2025 guidance falls short of expectations",
            "description": "<html><body><ul> <li>Although Pfizer (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/PFE\" title=\"Pfizer Inc.\">PFE</a></span>) reiterated 2025 financial guidance issued in December, the midpoints of the ranges for revenue and EPS are below consensus figures. </li> <li>The pharmaceutical giant is projecting revenue of $61B-$64B (midpoint $62.5B) this year. Consensus is $63B. EPS is estimated at $2.80-$3.00 (midpoint $2.90). Consensus is $2.93. </li> <li class=\"paywall-full-content invisible\">In Q4, Pfizer <a href=\"https://seekingalpha.com/news/4402570-pfizer-non-gaap-eps-of-0_63-beats-by-0_17-revenue-of-17_8b-beats-by-540m\" target=\"_self\" title=\"beat\">beat</a> on both the top and bottom lines.</li> <li class=\"paywall-full-content invisible\">In the quarter, Pfizer saw its biggest revenue gains, percentage-wise, in primary care and oncology, which both saw 27% year-over-year growth. Eliquis (apixaban), which the drugmaker markets with Bristol-Myers Squibb (<a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a>), remained its top-selling drug, with ~$1.8B in revenue, a 14% increase compared to Q4 2023.</li> <li class=\"paywall-full-content invisible\">Vyndaqel and Vyndamax (tafamidis) saw the biggest year-over-year percentage gain in revenue, rising 61% to ~$1.5B.</li> <li class=\"paywall-full-content invisible\">The company noted it is on schedule to achieve ~$4.5B in cost savings by the end of the year as part of an ongoing cost realignment program. </li> </ul> </body></html>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689040811/image_1689040811.jpg",
            "link": "https://seekingalpha.com/news/4402612-pfizer-2025-guidance-falls-short-expectations",
            "pub_date": "2025-02-04 16:27:30",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402650",
            "title": "VICI Properties announces new $2.5B unsecured credit facility",
            "description": "<html><body><p dir=\"ltr\">VICI Properties (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/VICI\" title=\"VICI Properties Inc.\">VICI</a></span>) <a href=\"https://seekingalpha.com/pr/19990342-vici-properties-inc-announces-new-2_5-billion-unsecured-credit-facility\" rel=\"noopener\" target=\"_blank\" title=\"announced\">announced</a> on Tuesday the effectiveness of its new $2.5B multicurrency unsecured revolving credit facility that replaced its existing, and now terminated, unsecured revolving credit facility of the same size.</p> <p dir=\"ltr\">The revolving credit facility was substantially oversubscribed with<span class=\"paywall-full-content invisible\"> strong support from 15 financial institutions.</span></p> <p class=\"paywall-full-content invisible\" dir=\"ltr\">The revolving credit facility matures on February 3, 2029, and can be extended for two successive six-month terms or one twelve-month term. </p> <p class=\"paywall-full-content invisible\" dir=\"ltr\">Based on a pricing grid and the company’s current credit ratings and leverage ratios, the revolving credit facility currently bears interest at a rate of 85 basis points over the SOFR rate or, in the case of borrowings in a foreign currency, the corresponding index rate for such currency. </p> <p class=\"paywall-full-content invisible\" dir=\"ltr\">In addition, based on the company’s current credit ratings and leverage ratios, the revolving credit facility requires the payment of a facility fee of 20.0 basis points of total commitments. </p> <p class=\"paywall-full-content invisible\" dir=\"ltr\">The company has an option to increase the revolving credit facility by up to $1B, to the extent that any one or more lenders agree to provide such additional credit extensions.</p> <p class=\"paywall-full-content invisible\"> </p> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402650-vici-properties-announces-new-2_5b-unsecured-credit-facility",
            "pub_date": "2025-02-04 16:29:35",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402653",
            "title": "KKR & Co. declares $0.175 dividend",
            "description": "<html><body><ul> <li>KKR &amp; Co. (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/KKR\" title=\"KKR &amp; Co. Inc.\">KKR</a></span>) declared <a href=\"https://ir.kkr.com/media/document/303ebb79-89b5-4026-8422-130803394f8d/assets/KKR%20Q424%20Earnings%20Release.pdf?disposition=inline\" rel=\"nofollow\" target=\"_blank\">$0.175/share quarterly dividend</a>, in line with previous.</li> <li> <a href=\"https://seekingalpha.com/symbol/KKR/dividends/yield?source=news_bullet\">Forward yield</a> 0.43%</li> <li>Payable Feb. 28; for shareholders of record Feb. 14; ex-div Feb. 14.</li> <li>Beginning with the dividend to be announced with the results of the quarter<span class=\"paywall-full-content invisible\"> ending March 31, 2025, KKR intends to increase its regular annualized dividend per share of common stock from $0.70 to $0.74.</span> </li> <li class=\"paywall-full-content invisible\"><a href=\"https://seekingalpha.com/symbol/KKR/dividends?source=news_bullet\">See KKR Dividend Scorecard, Yield Chart, &amp; Dividend Growth.</a></li> </ul> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402653-kkr-and-co-declares-0_175-dividend",
            "pub_date": "2025-02-04 16:24:19",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402654",
            "title": "Comstock subsidiary approved for $152M allocation for Oklahoma qualified private activity bonds",
            "description": "<html><body><div><ul> <li>Comstock (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/LODE\" title=\"Comstock Inc.\">LODE</a></span>) announced that its subsidiary, Comstock Fuels, was approved by the Oklahoma State Treasurer’s Office to issue up to $152M in qualified private activity bonds.</li> <li>This overall approval by the Oklahoma State Treasurer’s Office comes under the Oklahoma Private<span class=\"paywall-full-content invisible\"> Activity Bond Allocation Act and would consist of allocations from the Oklahoma Economic Development Pool, the Oklahoma Exempt Facilities Pool, and the Oklahoma Carryforward Pool.</span> </li> <li class=\"paywall-full-content invisible\">LODE shares rise 5.5% premarket on Tuesday.</li> <li class=\"paywall-full-content invisible\">Source: <a href=\"https://seekingalpha.com/pr/19990075-comstock-fuels-approved-for-152-million-allocation-for-oklahoma-qualified-private-activity\">Press release</a> </li> </ul></div> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402654-comstock-subsidiary-approved-for-152m-allocation-for-oklahoma-qualified-private-activity-bonds",
            "pub_date": "2025-02-04 16:25:26",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402640",
            "title": "McKesson to take 80% interest in PRISM Vision for about $850M",
            "description": "<html><body><p class=\"MsoNormal\">McKesson (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/MCK\" title=\"McKesson Corporation\">MCK</a></span>) has agreed to acquire an 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, from Quad-C for about $850M.</p> <p class=\"MsoNormal\">PRISM Vision physicians will continue to retain a 20% interest in PRISM Vision. The transaction is<span class=\"paywall-full-content invisible\"> subject to customary closing conditions, including necessary regulatory clearances.</span></p> <p class=\"MsoNormal paywall-full-content invisible\">This transaction will enable McKesson to develop a leading retinal and ophthalmology platform. PRISM affiliated practices include more than 180 providers, 91 office locations and seven ambulatory surgery centers</p> <p class=\"MsoNormal paywall-full-content invisible\">Following completion of the transaction, PRISM Vision will be consolidated within McKesson’s U.S. Pharmaceutical segment.</p> <p class=\"MsoNormal paywall-full-content invisible\">Upon closing, PRISM Vision is expected to be around $0.20 to $0.30 accretive to McKesson’s adjusted earnings per diluted share in the first 12 months, and $0.65 to $0.75 accretive by the end of the third year following close.</p> <p class=\"MsoNormal paywall-full-content invisible\">“The acquisition of PRISM Vision will allow McKesson to build on our leadership in community practice and specialty solutions, while building a platform to serve the high-growth area of retina and ophthalmology,” said Brian Tyler, chief executive officer of McKesson.</p> <p class=\"paywall-full-content invisible\">Source: <a href=\"https://seekingalpha.com/pr/19990372-mckesson-advances-specialty-leadership-signs-agreement-to-acquire-controlling-interest-in\">Press Release</a></p> </body></html>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299649026/image_1299649026.jpg",
            "link": "https://seekingalpha.com/news/4402640-mckesson-to-take-80-interest-in-prism-vision-for-about-850m",
            "pub_date": "2025-02-04 16:18:01",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402652",
            "title": "Oaktree Specialty Lending declares $0.40 dividend",
            "description": "<html><body><ul>\n<li>Oaktree Specialty Lending (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/OCSL\" title=\"Oaktree Specialty Lending Corporation\">OCSL</a></span>) declared <a href=\"https://seekingalpha.com/pr/19990039-oaktree-specialty-lending-corporation-announces-first-fiscal-quarter-2025-financial-results\" target=\"_blank\">$0.40/share quarterly dividend</a>.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/OCSL/dividends/yield?source=news_bullet\">Forward yield</a> 10.03%</li>\n<li>The Board of Directors also declared a supplemental distribution of $0.07 per share.</li>\n<li>Payable March 31; for shareholders of record March 17; ex-div March 17.</li>\n<li>The company had <a href=\"https://seekingalpha.com/news/4306720-oaktree-specialty-lending-declares-055-dividend\">declared</a> of $0.55 per share quarterly cash distribution in November 2024.</li>\n<li><a href=\"https://seekingalpha.com/symbol/OCSL/dividends?source=news_bullet\">See OCSL Dividend Scorecard, Yield Chart, &amp; Dividend Growth.</a></li>\n</ul>\n</body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402652-oaktree-specialty-lending-declares-0_40-dividend",
            "pub_date": "2025-02-04 16:20:30",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402645",
            "title": "Fox Non-GAAP EPS of $0.96 beats by $0.34, revenue of $5.08B beats by $260M",
            "description": "<html><body><ul> <li>Fox <a href=\"https://seekingalpha.com/pr/19990437-fox-reports-second-quarter-fiscal-2025-revenues-of-5_08-billion-net-income-of-388-million-and\">press release</a> (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/FOX\" title=\"Fox Corporation\">FOX</a></span>): Q2 Non-GAAP EPS of $0.96 <span class=\"green\"> beats by $0.34</span>.</li> <li>Revenue of $5.08B (+20.1% Y/Y) <span class=\"green\"> beats by $260M</span>.</li> <li>Quarterly Adjusted EBITDA was $781 million, an increase of $431 million or 123% from the amount reported in the prior year quarter.</li> <li class=\"paywall-full-content invisible\">The company has declared a dividend of $0.27 per Class A and Class B share. This dividend is payable on March 26, 2025 with a record date for determining dividend entitlements of March 5, 2025.</li> </ul> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402645-fox-non-gaap-eps-of-096-beats-by-034-revenue-of-508b-beats-by-260m",
            "pub_date": "2025-02-04 16:12:27",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402647",
            "title": "Mesa Laboratories Non-GAAP EPS of $2.72 beats by $1.21, revenue of $62.84M beats by $4.01M",
            "description": "<html><body><ul>\n<li>Mesa Laboratories <a href=\"https://seekingalpha.com/pr/19990461-mesa-labs-announces-third-quarter-results\">press release</a>  (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/MLAB\" title=\"Mesa Laboratories, Inc.\">MLAB</a></span>): Q3  Non-GAAP EPS of $2.72 <font color=\"green\"> beats by $1.21</font>.</li>\n<li>Revenue of $62.84M (+17.5% Y/Y) <font color=\"green\"> beats by $4.01M</font>.</li>\n<li>\n<em>Non-GAAP core organic revenues</em><sup>1 </sup><em>increase was 13.2%.</em>\n</li>\n<li>\n<em>Non-GAAP adjusted operating income excluding unusual items</em><sup>2</sup><em> increased 13.3% and was 23.5% as a percentage of revenues.</em>\n</li>\n<li>Total Net Leverage Ratios* as of March 31, 2024, June 30, 2024 and September 30, 2024 were 3.84x, 3.78x, and 3.59x, respectively.</li>\n</ul>\n</body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402647-mesa-laboratories-non-gaap-eps-of-272-beats-by-121-revenue-of-6284m-beats-by-401m",
            "pub_date": "2025-02-04 16:15:38",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402636",
            "title": "Intuitive Machines to redeem outstanding warrants",
            "description": "<html><body><ul> <li dir=\"ltr\">Intuitive Machines (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/LUNR\" title=\"Intuitive Machines, Inc.\">LUNR</a></span>) <a href=\"https://seekingalpha.com/pr/19990288-intuitive-machines-announces-redemption-of-outstanding-warrants\" rel=\"noopener\" target=\"_blank\" title=\"said\">said</a> on Tuesday that it has delivered a notice of redemption to redeem all of its outstanding warrants to purchase shares of the company’s Class A common stock, $0.0001 par value per share, that were issued under<span class=\"paywall-full-content invisible\"> the Warrant Agreement, dated as of September 21, 2021, for a redemption price of $0.01 per warrant. </span> </li> <li class=\"paywall-full-content invisible\" dir=\"ltr\">Under the terms of the Warrant Agreement, the company has the right to redeem all the outstanding warrants if the last sales price of the Class A Common Stock is at least $18 per share for any 20 trading days within any 30-day trading period ending on the third business day before the date on which a notice of redemption is given. </li> <li class=\"paywall-full-content invisible\" dir=\"ltr\">The last sales price of the Class A Common Stock has been at least $18 per share on each of 20 trading days within the 30-day trading period ending on January 30, 2025. </li> <li class=\"paywall-full-content invisible\" dir=\"ltr\">Intuitive Machines (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/LUNR\" title=\"Intuitive Machines, Inc.\">LUNR</a></span>) shares were <span style=\"color: #008000;\">up 2.49%</span> in pre-market trading. </li> </ul> </body></html>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368368019/image_1368368019.jpg",
            "link": "https://seekingalpha.com/news/4402636-intuitive-machines-to-redeem-outstanding-warrants",
            "pub_date": "2025-02-04 16:08:31",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402641",
            "title": "DIH expands strategic partnership with Zahrawi Group",
            "description": "<html><body><ul> <li>DIH Holding (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/DHAI\" title=\"DIH Holding US, Inc.\">DHAI</a></span>) has announced the expansion of their <a href=\"https://seekingalpha.com/pr/19990290-dih-expands-strategic-partnership-with-zahrawi-group\">strategic partnership</a> with Zahrawi Group, DIH's representative and sales partner, to include Saudi Arabia.</li> <li>The expansion aims to enhance the distribution and accessibility of DIH's innovative rehabilitation solutions across these regions, leveraging<span class=\"paywall-full-content invisible\"> Zahrawi Group's established presence and expertise in the healthcare sector. </span> </li> <li class=\"paywall-full-content invisible\">The collaboration will focus on delivering state-of-the-art technologies to improve patient outcomes and support healthcare professionals with cutting-edge tools.</li> <li class=\"paywall-full-content invisible\">By combining DIH's technological expertise with Zahrawi Group's (MTC Company) regional experience, the collaboration is poised to make a meaningful impact on rehabilitation services delivery in the Middle East.</li> <li class=\"paywall-full-content invisible\">\"Extending our partnership with DIH aligns with our mission to provide smart solutions, innovative products, and outstanding services to improve people's lives every day,\" said Abdulrahman Ramadan, Group CEO of Zahrawi Group.</li> </ul> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402641-dih-expands-strategic-partnership-with-zahrawi-group",
            "pub_date": "2025-02-04 16:08:55",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        }
    ]
}